Digital & Innovation

Organon and J&J digital leaders explore emerging trends and dynamics shaping 2022 at Digital Acceleration Roundtable

Health Industry Hub | November 29, 2021 |
[Total: 1    Average: 5/5]

Digital & Innovation: The COVID-19 pandemic has accelerated the adoption of digital transformation in the pharma and medtech sectors. Organisations are investing in digital expertise to understand the gaps and determine the right digital strategies and investment required in meeting their stakeholder needs.

Geoff Quattromani, Digital Transformation Manager at Johnson & Johnson Medical and Sally Dunstan, Customer Experience and Digital Healthcare Marketing at Organon ANZ joined Health Industry Hub Founder Rozalina Sarkezians and co-host Peter Stephenson from West 53rd St Digital for the fourth Digital Acceleration Roundtable to explore the emerging new digital trends impacting industry this year and the key digital dynamics shaping 2022.

The panellists also discussed the critical success factors for omnichannel marketing as a strategic priority, the major opportunities to enhance customer engagement, and the role of data and artificial intelligence (AI) in delivering smarter, more efficient customer engagement models.

In reflecting on the emerging new digital trends that will be impacting the medtech and pharma industries, Geoff Quattromani said “QR codes, virtual and augmented reality have been around for many years but the real world really got to start using and experiencing them through the pandemic. At the moment, it might just be to check into a venue to say that you’re there and comply with COVID rules, but why not when I pick up a garment off the shelf that instead of having that long tag, it just has a QR code where I can see what was in the garment, but actually where it was made and a story about the product. QR codes will change how we experience things in 2022.”

Sally Dunstan added “I’ve really enjoyed watching the rise of investment in the femtech space as a bit of a trend. We’re going to see huge innovations in that space over the next couple of years. The way in which women manage their healthcare needs, where they manage them and the requirements around that in the tech space is really exciting. It can be hugely impactful on women and their families and have a positive social impact.”

Geoff commented “It wasn’t until we were sent home to start living and working from home that we realised we could use these technologies [virtual reality and augmented reality] for different purposes. Virtual reality has been used a lot at J&J to reconnect people or to take people to places where you have shared experiences together. Whether it’s for training purposes or sales purposes, I think we’re going to see those types of technologies lift dramatically in 2022 because we need to think of different ways to engage one another in digital ways.”

You may also like to explore Key trends transforming industry workforce and the recruitment ecosystem in 2022

Human Resources

PAIG co-chairs reflect on industry progress in D&I with sights set on next phase goals

Health Industry Hub | January 17, 2022 |

Human Resources: In this Health Industry Hub podcast, Medicines Australia’s PAIG (Pharma Australia Inclusion Group) co-chairs reflect on their contribution […]


News & Trends - Medical Technology

MedTech News -

Stryker announces fellowships for medtech partner projects

Health Industry Hub | January 17, 2022 |

MedTech News: Stryker announced two of its partner research projects have secured fellowship funding from the Australian government’s Researcher Exchange […]


News & Trends - Pharmaceuticals

Pharma News - New guidelines recommend Eli Lilly and GSK drugs in treating COVID-19 patients

New guidelines recommend Eli Lilly and GSK drugs in treating COVID-19 patients

Health Industry Hub | January 17, 2022 |

Pharma News: Update to international guidelines recommend two new drugs for the treatment of COVID-19. Eli Lilly’s oral JAK inhibitor, […]


News & Trends - Pharmaceuticals

Pharma News -

Novartis shifts focus as CAR T-cell therapy fails to add benefit in non-Hodgkin lymphoma

Health Industry Hub | January 17, 2022 |

Pharma News: Novartis’ chimeric antigen receptor (CAR) T-cell therapy was not found to improve event-free survival over what was seen […]